Overcoming challenges, increasing yields

In efforts to bring the next-generation of plasmid technology to the cell and gene therapy space, Aldevron is offering a giveaway to customers developing AAV based therapies. Nanoplasmid benefits in the context of AAV include improved ITR stabilization from its proprietary host strain while increasing plasmid yields compared to conventional plasmid vectors. 

Advantages of the Nanoplasmid RNA-OUT Marker System

For decades, the same plasmid technology has been used in vaccination, cell and gene therapy, and as a raw material in viral vector and RNA production, but that technology often isn’t a good fit for the processes where it’s being used. Now, with the growing availability of Nanoplasmid™ vectors, that is changing.

Downstream challenges in mRNA production

In my previous post, I brought up important questions that should be asked when beginning to design a scalable manufacturing process to meet specific use requirements. In this post, some of the difficulties encountered in process development are reviewed.

Production paths to mRNA

My last post gave a short introduction to the manufacture of in vitro transcribed (IVT) messenger RNA (mRNA) for vaccines and therapies, outlining the steps from preclinical to clinical stages of production. In this post, I’ll touch on manufacturing considerations, beginning with the upstream process for IVT mRNA.

Driving innovation of industry tools

Analytical innovation is often overlooked in discussions of biotechnology product development and manufacturing processes. For example, in the DNA area, most “state of the art” analytical methods in use were developed in the 1980s, or even earlier. Industrywide, there is a need to continuously innovate in the analytical space due to the tremendous advances in enabling technologies.

Nanoplasmid™ Vectors: The Power of Small

In cell and gene therapies, delivery is a critical factor. Regardless of your modality, optimizing payload, impact, and duration are common challenges. Countless programs, globally, are working on the delivery mechanism. However, many have overlooked a key component in improving therapeutic or manufacturing performance: the plasmid.

New ITR Cloning and Reporter Constructs Now Available

By Jeff Briganti, Senior Director, Global Strategic Marketing

Manufacturing standardization for cell and gene therapies (C&GT) has received increased focus in the last several years, spurred by the rapid exponential growth witnessed in this field. The resulting need for improved access to high-quality raw materials, including plasmid DNA, has made standardization integral to streamlining the development process for this biologic product category.

For recombinant adeno-associated virus (rAAV) viral vector production, we now offer several off-the-shelf ITR cloning backbones and GFP reporter constructs to complement our standardized set of OTS helper and packaging plasmids. This product set is available license and royalty free for research through commercial rAAV applications.

Utilizing this standardized portfolio can provide significant time and cost reduction, expediting time to market and de-risking specialized, transformative therapeutic development. By partnering with a contract development and manufacturing organization (CDMO) offering a complete suite of plasmids for viral vector production, researchers can streamline their upfront development while minimizing supply chain disruption throughout their program’s lifecycle.

For full information about our new product offering or to request a sample, visit our pALD-ITR Products page.

• Want to learn more about this topic? Contact Jeff Briganti with your questions
• Have an idea for a topic? Let us know!

One of the many ways we can help you streamline your project is by offering free cloning backbones that have been tested in our production systems. We have recently expanded our portfolio to meet the increasing demands for backbones specifically for RNA production.